NCT05788289终止2 期
Phase 2 Study of Tafasitamab and Lenalidomide in Relapsed or Refractory Mantle Cell Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 4
- 试验地点
- 7
- 主要终点
- Overall Response Rate/ORR
研究概览
简要总结
The purpose of this study is to determine if the combination of tafasitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years at the time of signing Informed Consent
- •Karnofsky performance status (KPS) ≥ 70% (see Appendix A)
- •Pathologically confirmed diagnosis of R/R MCL
- •Previously treated with at least one prior line of systemic therapy for MCL, at least one of which must have been a BTKi
- •If patient previously received CD19-directed therapy (such as CAR-T therapy), then there must be evidence of CD19 expression confirmed by immunohistochemistry or flow cytometry per institutional guidelines. This must be confirmed on a biopsy performed after receipt of CD19-directed therapy.
- •Previous systemic chemotherapy must have been discontinued at least 2 weeks prior to C1D1 and previous anti-cancer radiation therapy or targeted therapy must be discontinued prior to initiation of treatment on study
- •All adverse effects should resolve to grade 1 or baseline (excluding alopecia)
- •Presence of evaluable disease
- •Measurable disease on radiologic assessment as defined by Lugano criteria: at least one nodal lesion (> 1.5cm in long axis) or extranodal lesion (> 1.0cm in long axis) measurable in 2 dimensions1,2
- •Adequate bone marrow and organ function:
- •Absolute neutrophil count (ANC) ≥ 1,500 cells/mcL, unless felt to be secondary to underlying MCL
- •Platelet count ≥ 90,000 cells/mcL, unless felt to be secondary to underlying MCL
- •Renal function assessed by calculated Cockcroft-Gault creatinine clearance (CrCl; see Appendix B) ≥ 30mL/min. See 10.0 Treatment Plan, Table 10-1, for lenalidomide dose adjustment for CrCl ≥ 30mL/min and < 60mL/min.
- •Hepatic function:
- •Total bilirubin < 2.5x upper limit of normal (ULN), unless secondary to Gilbert's syndrome or documented liver involvement by lymphoma. Patients with Gilbert's syndrome or documented liver involvement by lymphoma may be included if total bilirubin is ≤ 5x ULN.
- •Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3x ULN, unless secondary to documented liver involvement by lymphoma. Patients with documented liver involvement by lymphoma may be included if AST and ALT are ≤ 5x ULN.
- •Willingness to receive adequate prophylaxis and/or therapy for thromboembolic events, unless contraindicated in the opinion of the investigator
- •Willingness to undergo confirmatory procedures for assessment of disease status and experimental studies as required by protocol, including bone marrow (BM) aspiration/biopsy, gastrointestinal endoscopy/colonoscopy with biopsy, and/or biopsy of other tissue when appropriate and medically feasible
- •Each patient must sign Informed Consent form indicating that he or she understands the purpose of and procedures required for the study and are willing to participate
- •Short course systemic corticosteroids (total daily dose equivalent of prednisone 100mg or less) are permissible for disease control, improvement of performance status, or non-cancer indication if administered for ≤ 10 days and discontinued prior to initiation of study treatment
- •Willingness of patients who are able to become pregnant according to Revlimid/lenalidomide Risk Evaluation and Mitigation Strategy (REMS) criteria to undergo pregnancy testing in accordance with REMS requirements
- •Willingness of all patients to adhere to contraception requirements mandated by the Revlimid/lenalidomide REMS
排除标准
- •Any life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the patient's safety or put the study outcomes at undue risk
- •History of human immunodeficiency virus (HIV) unless all of the following criteria are met:31
- •CD4+ T-cell count ≥ 250 cells/mcL
- •No acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within 1 year prior to signing Informed Consent form
- •Stable (no change in regimen for ≥ 4 weeks) and effective antiretroviral regimen, and HIV viral load < 400 copies/mL within 4 weeks prior to signing Informed Consent form
- •Hepatitis B or C with detectable viral load requiring antiviral therapy
- •Pregnant or lactating
- •Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 2 weeks prior to cycle 1 day 1
- •Clinical significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
- •Active central nervous system lymphoma
- •Patients who, in the opinion of the investigator, have not recovered sufficiently from adverse effects of prior therapies
- •Documented refractoriness to lenalidomide, defined as no response (PR or CR) within 6 months of therapy
- •Lenalidomide exposure within 12 months prior to Day 1 of Cycle 1
- •History of hypersensitivity to compounds of similar biological or chemical composition to tafasitamab, lenalidomide, and/or excipients contained in the study drug formulations
- •Autologous stem cell transplantation (ASCT) within 3 months prior to signing the Informed Consent form. Patients with more distant history of ASCT must exhibit full hematologic recovery before enrollment into this study.
- •Allogeneic stem cell transplantation within 3 months prior to signing the Informed Consent form, with evidence of graft-versus-host disease (GVHD), or receiving immunosuppressive therapy for GVHD.
- •Concurrent use of other anticancer or experimental treatments
- •No concurrent malignancy requiring active therapy within the last 3 years with the exception of basal cell carcinoma limited to the skin, squamous cell carcinoma limited to the skin, carcinoma in situ of the cervix or breast, adequately treated lentigo maligna melanoma, or localized prostate cancer. Adjuvant or maintenance therapy to reduce the risk of recurrence of other malignancy previously treated for curative intent is permitted.
- •Administration of a live vaccine within 28 days prior to the start of study treatment (Cycle 1 Day 1).
研究组 & 干预措施
Participants with Mantle Cell Lymphoma
Experimental
Participants have a diagnosis of Mantle Cell Lymphoma have previously failed or could not tolerate Bruton's tyrosine kinase inhibitors/BTKi
干预措施: Tafasitamab (Drug)
Participants with Mantle Cell Lymphoma
Experimental
Participants have a diagnosis of Mantle Cell Lymphoma have previously failed or could not tolerate Bruton's tyrosine kinase inhibitors/BTKi
干预措施: Lenalidomide (Drug)
结局指标
主要结局
Overall Response Rate/ORR
时间窗: completion of 12 cycles of treatment (each cycle is 28 days) or at treatment discontinuation, whichever comes first
Overall Response Rate/ORR is defined as the percent of participants who achieve Complete Response/CR or Primary Response/PR
次要结局
未报告次要终点
研究者
研究点 (7)
Loading locations...
相似试验
招募中
2 期
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell LymLarge B-cell LymphomaNCT06760156H. Lee Moffitt Cancer Center and Research Institute28
进行中（未招募）
2 期
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular LymphomaRecurrent High Grade B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeRecurrent Primary Mediastinal (Thymic) Large B-Cell LymphomaRecurrent T-Cell/Histiocyte-Rich Large B-Cell LymphomaRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaRecurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRefractory Grade 3b Follicular LymphomaRefractory High Grade B-Cell Lymphoma, Not Otherwise SpecifiedRefractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeRefractory Primary Mediastinal (Thymic) Large B-Cell LymphomaRefractory T-Cell/Histiocyte-Rich Large B-Cell LymphomaRefractory Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaRefractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell LymphomaNCT05821088David Bond, MD37
进行中（未招募）
3 期
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)Large B-Cell LymphomaDiffuse Large B-Cell LymphomaNCT05429268Incyte Corporation82
招募中
1 期
Tafasitamab Plus Lenalidomide in Relapsed CNS LymphomaCNS LymphomaPrimary Central Nervous System LymphomaSecondary Central Nervous System LymphomaNCT05351593James Rubenstein35
招募中
2 期
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecurrent Mantle Cell LymphomaRefractory Mantle Cell LymphomaNCT05910801Academic and Community Cancer Research United100